The phase 2 BRIDGE study is an open-label, single-arm study, designed to evaluate the pharmacokinetics, safety and efficacy of melflufen in combination with dexamethasone in multiple myeloma patients with reduced renal function.

Patients with Multiple myeloma commonly have impaired renal function. The BRIDGE study intended to demonstrate how melflufen can be used in relapsed refractory multiple myeloma patients with renal impairment.

The study started in Q3 2018 and included 35 patients. The study was terminated in December 2021 and the results have been presented.